AIMT has long term potential.

4 дек. 2018 г.

AIMT has just hit the all time 52 week low today. They've recently published good news on their AR101 clinical results and with no life threatening adverse results. There is a high percentage of probability the BLA will be granted Fast track designation by the FDA, based on recent data results. The question is not if, but when this gem of a security will take-off.

7 янв. 2019 г.

Заметка

On January 4th, AAIMT announced a 170MM loan agreement with KKR to fund the commercialization of AR101 pipeline. Quick recap, December was rough terrain for the entire market. What really impressed me is the resilience and performance we are observing out of AAIMT under such adverse conditions.

On a more concrete analysis, the following is a personal analysis and is not intended for investment purposes. "Based on a U.S. statistical population reported in January 7th, 2019 accrues a total population of 327.9MM. A market analysis for peanut allergies is estimated at an annual rate of 16,396,767 same as 5% of overall population.

For those that may be unaware, we are talking about an untapped medical condition which has a history resulting in life threatening reactions that send adults and children to the E.R. every year. Projections for annual U.S. market of AR101 falls in the range of 1.6B which will compound on annual basis."